In patients with psoriatic arthritis (PsA), their sex matters. In the session Sex Differences in Psoriatic Arthritis, Laura Coates, MD, PhD, of the University of Oxford, and Lihi Eder, MD, PhD, of the University of Toronto, will discuss sex-related differences in clinical features, disease course, treatment response and pain perception in patients with PsA. The…
Two studies outline the roles of air pollution and T cell imbalance in the pathogenesis of systemic lupus erythematosus.
It was like a reverse Uno card had been thrown onto the table. My patient was now asking his rheumatologist, “Are you okay? You look like you’re in a lot of pain.” He was right. I was wincing trying to get up from my seat and limping trying to get a few steps over to…
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
Dr. Laurent Arnaud highlighted the latest information on systemic lupus erythematosus (SLE), including genetics, technology, treat to target, and promising findings for pulse therapy in his session at EULAR 2024.
Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.
Although research is still emerging, evidence suggests changes in climate, such as increases in heat, pollution and allergens, may increase the risk of flare and hospitalization in patients with rheumatoid arthritis, systemic lupus erythematosus and other rheumatic conditions. Paul Dellaripa, MD, discussed the research and how rheumatologists can help their patients.
Dr. Jens Thiel provided a detailed overview of specific treatments for patients with immunoglobulin A (IgA) vasculitis and IgA nephropathy, highlighting treatments in early clinical trials.
Background & Objectives The ORAL Surveillance trial (NCT02092467), a postauthorization safety study of tofacitinib in patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor, found a dose-dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events when patients were treated with tofacitinib vs. a tumor…
Magdalena “Maggie” Cadet, MD, a rheumatologist in New York City, remembers learning about the relationship between physical activity and bone health at a young age. She was 5 years old when she first began taking ballet, jazz and tap-dancing lessons. At 9, she became a competitive figure skater and practiced both dance and ice skating…